# REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER

> **NCT06826677** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 71 (actual)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT06826677
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-30
- **Primary completion:** 2025-01-23
- **Final completion:** 2025-01-23
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826677, "REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06826677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*